SCHEMBL24804244

SCHEMBL24804244

COC(=O)[C@H](CNC(=O)N[C@@H]1CCc2ccccc21)NC(=O)c1c(Cl)ccc(NCCc2ccccc2)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.49
USP2 O75604 1/20 0.44
TAS1R3 Q7RTX0 6/20 0.41
TAS1R1 Q7RTX1 6/20 0.41
TAS1R2 Q8TE23 4/20 0.41
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.38
BACE1 P56817 1/20 0.36
KCNA5 P22460 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978664 1.00 EPHX2 (0.49) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL24805424 1.00 EPHX2 (0.49) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL30279322 1.00 EPHX2 (0.49) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL23979059 0.95 EPHX2 (0.54) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL24803329 0.95 EPHX2 (0.54) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL26494810 0.95 EPHX2 (0.54) EPHX2USP2TAS1R3TAS1R1TAS1R2
SCHEMBL23978666 0.92 EPHX2 (0.52) EPHX2TAS1R3TAS1R1TAS1R2HTT
SCHEMBL23979034 0.92 EPHX2 (0.52) EPHX2TAS1R3TAS1R1TAS1R2HTT
SCHEMBL30279460 0.92 EPHX2 (0.52) EPHX2TAS1R3TAS1R1TAS1R2HTT
SCHEMBL23978602 0.92 EPHX2 (0.52) EPHX2TAS1R3TAS1R1TAS1R2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 EPHX2 1037/4885USP2 1793/4885TAS1R3 1142/4885
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF ITGB1, ITGB2, ITGA2 EPHX2 1037/4885USP2 1793/4885TAS1R3 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.